MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Free Cash flow
-$5,194K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Sales and maturities of marketab...
Deposit received for the sale of...
Depreciation and amortization
Others
Negative Cash Flow Breakdown
Share repurchases
Purchases of marketable securiti...
Other assets and liabilities
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Net loss
2,456
-160,798
-15,432
50,839
Depreciation and amortization
13,580
14,002
13,648
14,434
Impairment of goodwill and intangible assets
0
149,083
-
0
Non-cash gain from settlement of preexisting contractual relationship
0
3,858
-
-
Loss on assets held for sale
-6,474
6,269
9,696
93
Property, plant and equipment and other asset write-offs
-
-
-
3,478
Inventory write-downs
-
-
-
0
Other non-cash charges related to restructuring and transformation
-
-
-
0
Inventory write-downs and other non-cash items
-582
2,188
-4,171
-
Stock-based compensation
4,812
6,362
4,058
4,994
Contingent consideration adjustment
-
-
-
0
Amortization and accretion on marketable securities
406
308
374
260
Deferred income taxes
1,735
490
-5,788
-7,013
Purchase accounting impact on inventory
-
-
-
0
Loss on disposals of property, plant and equipment
5
-61
42
48
Accounts receivable
4,468
-7,818
-723
17,760
Inventories
2,801
-3,029
9,729
-7,398
Accounts payable
3,725
-8,952
4,572
1,739
Deferred revenue
-5,155
3,946
3,195
-6,515
Accrued warranty and retrofit costs
206
126
-248
-471
Accrued compensation and tax withholdings
2,429
-1,087
-5,158
4,417
Long term income taxes receivable
-
-
-
45,600
Accrued restructuring costs
-480
257
300
-
Other assets and liabilities
7,127
5,115
-21,782
3,740
Net cash provided by operating activities
1,445
13,513
20,847
2,170
Purchases of property, plant and equipment
6,639
7,403
6,192
7,860
Purchases of marketable securities
36,523
220,143
108,692
138,419
Sales and maturities of marketable securities
29,019
123,814
142,656
146,925
Acquisition of uk biocentre, net of cash acquired
133
11,017
-
0
Proceeds from other investment
0
0
-
0
Net investment hedge settlement
0
0
-
180
Deposit received for the sale of b medical systems business
19,000
0
9,000
-
Net cash used in investing activities
4,724
-114,749
36,772
826
Proceeds from issuance of common stock
-1
1,179
-
1,217
Payments of finance leases
172
197
214
400
Withholding tax payments on net share settlements on equity awards
101
2
2,418
0
Excise tax payment for settled share repurchases
0
0
0
0
Share repurchases
50,046
-
-
0
Net cash used in financing activities
-50,320
980
-2,632
817
Effects of exchange rate changes on cash, cash equivalents and restricted cash
-466
-2,442
314
-944
Net decrease in cash, cash equivalents and restricted cash
-44,617
-102,698
55,301
2,869
Cash, cash equivalents and restricted cash, beginning of period
351,986
351,986
296,685
320,990
Cash, cash equivalents and restricted cash, end of period
204,671
-
-
-
Cash paid for income taxes, net
7,017
-
-
-
Purchases of property, plant and equipment included in accounts payable and accrued expenses
6,978
-
-
-
Cash and cash equivalents of continuing operations
189,654
-
-
-
Cash included in current assets held for sale
8,363
-
-
-
Short-term restricted cash
2,414
-
-
-
Long-term restricted cash included in other assets
4,240
-
-
-
Total cash, cash equivalents and restricted cash shown in the condensed consolidated statements of cash flows
204,671
249,288
351,986
296,685
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Sales and maturities
of marketable...
$29,019K
(-88.03%↓ Y/Y)
Depreciation and
amortization
$13,580K
(-70.97%↓ Y/Y)
Deposit received for the
sale of b medical...
$19,000K
Stock-based compensation
$4,812K
(-69.71%↓ Y/Y)
Accounts payable
$3,725K
(630.63%↑ Y/Y)
Net loss
$2,456K
(102.30%↑ Y/Y)
Accrued compensation
and tax...
$2,429K
(-19.30%↓ Y/Y)
Deferred income taxes
$1,735K
(108.66%↑ Y/Y)
Accrued warranty and
retrofit costs
$206K
(472.22%↑ Y/Y)
Net cash used in
investing activities
$4,724K
(105.17%↑ Y/Y)
Net cash provided by
operating activities
$1,445K
(-97.94%↓ Y/Y)
Canceled cashflow
$43,295K
Canceled cashflow
$27,498K
Net decrease in
cash, cash...
-$44,617K
(-64.19%↓ Y/Y)
Canceled cashflow
$6,169K
Purchases of marketable
securities
$36,523K
(-88.33%↓ Y/Y)
Purchases of property,
plant and equipment
$6,639K
(-74.46%↓ Y/Y)
Acquisition of uk biocentre,
net of cash acquired
$133K
Other assets and
liabilities
$7,127K
(1232.15%↑ Y/Y)
Loss on assets held
for sale
-$6,474K
(-106.96%↓ Y/Y)
Deferred revenue
-$5,155K
(-172.04%↓ Y/Y)
Accounts receivable
$4,468K
(111.52%↑ Y/Y)
Inventories
$2,801K
(-72.18%↓ Y/Y)
Inventory write-downs and
other non-cash items
-$582K
(-115.05%↓ Y/Y)
Accrued restructuring
costs
-$480K
(-841.18%↓ Y/Y)
Amortization and accretion on
marketable securities
$406K
(-69.20%↓ Y/Y)
Loss on disposals of
property, plant and...
$5K
(100.66%↑ Y/Y)
Net cash used in
financing activities
-$50,320K
(-383.47%↓ Y/Y)
Effects of exchange rate
changes on cash, cash...
-$466K
(-110.33%↓ Y/Y)
Share repurchases
$50,046K
Payments of finance
leases
$172K
(-70.60%↓ Y/Y)
Withholding tax payments on
net share...
$101K
Proceeds from issuance of
common stock
-$1K
(-100.06%↓ Y/Y)
Buy us a coffee
Azenta, Inc. (AZTA)
Azenta, Inc. (AZTA)